Pharmaceutical packaging machinery manufacturers must upgrade their equipment to enable their customers to meet new regulatory obligations, process materials with different mechanical properties, and respond to the growing demand for automation and connectivity.
PMMI published in January 2026 the report “Trends and Challenges in Pharmaceutical Manufacturing”, based on surveys of international manufacturers and OEMs. Although the study is global in scope and analyzes global trends, it places special emphasis on the U.S. market.
In this note, amec extracts the seven most critical implications for packaging equipment manufacturers.
Digital connectivity has become a barrier to entry. The US DSCSA (Drug Supply Chain Security Act) requires full electronic traceability with deadlines in November 2025-2026.
Requirements:
_
Implications:
Market diversification penalizes single-product machines. The growth of injectables, blisters and ampoules forces format changes in minutes.
Requirements:
_
Implications:
Personnel costs in clean rooms make the incorporation of robots particularly cost-effective.
Requirements:
_
Implications:
Speed is a purchasing priority. The growth of new drugs generates the need for greater production capacity.
Requirements:
_
Implications:
Poorly designed machines require 2-3 hours of cleaning per day and generate problems in inspections. Correcting errors afterwards multiplies costs.
Requirements:
_
Implications:
The industry adopts recycled plastics, compostable materials and lightweight packaging, all of which behave differently from traditional materials.
Requirements:
_
Implications:
Many companies purchase new equipment specifically for GMP compliance, making it clear that the machines must actively facilitate legal compliance.
Requirements:
_
Implications:
PMMI. 2026 Trends and Challenges in Pharmaceutical Manufacturing
https://www.pmmi.org/report/2025-trends-and-challenges-in-pharmaceutical-manufacturing